Artykuł w czasopiśmie
Brak miniatury
Licencja

CC-BYCC-BY - Uznanie autorstwa

Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands

Autor
Tong, Kelvin K. H.
Budniok, Aleksandra
Hanif, Muhammad
Leśniewska, Barbara
Movassaghi, Sanam
Hartinger, Christian G.
Jamieson, Stephen M. F.
Söhnel, Tilo
Reynisson, Jóhannes
Zafar, Ayesha
Data publikacji
2020
Abstrakt (EN)

Ispinesib is a potent inhibitor of kinesin spindle protein (KSP), which has been identified as a promising target for antimitotic anticancer drugs. Herein, we report the synthesis of half-sandwich complexes of Ru, Os, Rh, and Ir bearing the ispinesib-derived N,N-bidentate ligands (R)- and (S)-2-(1-amino-2-methylpropyl)-3-benzyl-7-chloroquinazolin-4(3H)-one and studies on their chemical and biological properties. Using the enantiomerically pure (R)- and (S)-forms of the ligand, depending on the organometallic moiety, either the SM,R or RM,S diastereomers, respectively, were observed in the molecular structures of the Ru- and Os(cym) (cym = η6-p-cymene) compounds, whereas the RM,R or SM,S diastereomers were found for the Rh- and Ir(Cp*) (Cp* = η5-pentamethylcyclopentadienyl) derivatives. However, density functional theory (DFT) calculations suggest that the energy difference between the diastereomers is very small, and therefore a mixture of both will be present in solution. The organometallics exhibited varying antiproliferative activity in a series of human cancer cell lines, with the complexes featuring the (R)-enantiomer of the ligand being more potent than the (S)-configured counterparts. Notably, the Rh and Ir complexes demonstrated high KSP inhibitory activity, even at 1 nM concentration, which was independent of the chirality of the ligand, whereas the Ru and especially the Os derivatives were much less active.

Dyscyplina PBN
nauki chemiczne
Czasopismo
Inorganic Chemistry
Tom
59
Zeszyt
20
Strony od-do
14879-14890
ISSN
0020-1669
Data udostępnienia w otwartym dostępie
2020-10-01
Licencja otwartego dostępu
Uznanie autorstwa